Rabbit anti-G4S Linker Recombi
nant Monoclonal Antibody(Pacificblue Conjugate)(S-711-23)【兔抗G4S Linker重组单克隆抗体(Pacificblue结合物)(S-711-23)】- abs174240- ￥2500 - 4600
- Absin
- abs174240
- 上海
- 2025年08月22日
- FCM(Extra): 0.1μg per million cells in 100μl volume
- Rabbit
- 见优宁维官网
企业认证
相关产品推荐更多 >
AF488 Mouse anti-Human CD105 Antibody(43A3)【AF488 鼠抗人CD105抗体(43A3)】- abs1841181
￥1050
Rabbit anti-IL-23R Polyclonal Antibody【兔抗IL-23R多克隆抗体】
询价
Pulmonary Fibrosis MiniAb Kit【肺纤维化迷你抗体试剂盒】
￥4482
Rabbit anti-GPR42 Polyclonal Antibody【兔抗GPR42多克隆抗体】- abs149476
￥1500
Invivo anti-human CD32 (FcγRIIA) Recombinant Antibody【中文名称：Invivo 抗人 CD32 (FcγRIIA) 重组抗体】, 斯达特-国产抗体专家
￥9751
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Rabbit anti-G4S Linker Recombinant Monoclonal mAb(Pacificblue Conjugate)(S-711-23)
- 抗体英文名：
Rabbit anti-G4S Linker Recombinant Monoclonal Antibody(Pacificblue Conjugate)(S-711-23)
- 靶点：
见优宁维官网
- 浓度：
0.2 mg/mL
- 应用范围：
FCM(Extra): 0.1μg per million cells in 100μl volume
- 宿主：
Rabbit
- 适应物种：
见优宁维官网
- 保质期：
见优宁维官网
- 抗原来源：
见优宁维官网
- 级别：
优级
- 库存：
999
- 供应商：
Absin
- 标记物：
Pacific blue
- 克隆性：
S-711-23
- 保存条件：
Store at 4°C for one year. Avoid repeated freeze/thaw cycles.
- 免疫原：
Synthetic Peptide
- 规格：
100T/50T
| 规格： | 100T | 产品价格： | ￥4600.0 |
|---|---|---|---|
| 规格： | 50T | 产品价格： | ￥2500.0 |
别名：兔抗G4S Linker重组单克隆抗体(Pacificblue结合物)(S-711-23)
免疫原：Synthetic Peptide
应用：FCM(Extra): 0.1μg per million cells in 100μl volume
保持条件：Store at 4°C for one year. Avoid repeated freeze/thaw cycles.
使用方法：见优宁维官网
标记：Pacific blue
宿主：Rabbit
反应种属：见优宁维官网
克隆性：S-711-23
产品描述：见优宁维官网
爱必信品牌介绍：
更多详情请了解优宁维网站》》
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Monoclonal Antibody-Based Strategies in Autoimmunity and Transplantation
Monoclonal antibodies are homogeneous sets of immunoglobulins with well-defined specificity and biochemical characteristics. They were introduced into clinical practice in the early 1980s, and since then their use has rapidly expanded
Expression and Isolation of Recombinant Antibody Fragments in E. coli
Central to the rapid growth in the study and application of recombinant antibodies in recent years is the ability to reliably and cost-effectively produce large quantities of functional protein. In contrast to glycosylated whole monoclonal
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
